Liquid Dosage

Therapeutical Proteins

Protein-based therapeutics are increasingly being developed as new chemical entities in the pharmaceutical and life science industries. Unlike small molecules, which are typically synthesized using chemical processes, most proteins need to be processed in living systems, mostly by recombinant DNA technology. The proteins can then be produced in their functional form (quaternary structure), rather than by microbial biosynthesis (bacteria/yeast), substantially reducing the downstream stages of the process.

Downloads

GEA Insights

gea add better solutions

GEA products: pathway to resource efficiency

Costs for energy, water and raw materials are rising with efficiency becoming a decisive competitive factor. GEA identifies more resource-efficient successor solutions in a transparent way and has them independently validated. Now a portfolio of more than 50 products, what does it take to make the grade and how do customers benefit? GEA insiders share why these innovations are so transformative.

Chilling Danish pastries with purpose

German pastry specialist Wolf ButterBack expands with GEA’s ammonia-based BluX chiller technology that delivers flexible, low-maintenance cooling while helping the company move closer to net zero.

A partnership shaping the soul of pasta

Barilla and GEA unite tradition with innovation at a new R&D pilot plant in Illinois – boosting speed, flexibility & quality while keeping the soul of pasta alive. 🍝

Receive news from GEA

Stay in touch with GEA innovations and stories by signing up for news from GEA.

Need assistance?

We are here to help! With just a few details we will be able to respond to your inquiry.